

Ticker: **VTRS US EQUITY****Viatrix Inc (NASDAQ GS: VTRS, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website www.viatrix.com/en
 Number of Employees 32,000
 Ticker: VTRS US

1000 Mylan Blvd Canonsburg, PA 15317 United States
 Phone : 1-724-514-1800
 Fax : --

**9.27****-0.05**

-0.5%

-0.5%


Viatrix Inc. opera como una empresa farmacéutica. Produce medicamentos para pacientes en varias áreas terapéuticas principales que abarcan enfermedades no transmisibles e infecciosas. Atiende a pacientes en todo el mundo.

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	9.28	Market Cap (MM)	10,885.9
Open	9.29	Shares Out. (MM)	1,173.7
Previous Close	9.32	Float %	99.4%
Change	-0.02	Shares sold short (MM)	43,003,872.0
Change %	-0.21	Dividend Yield %	5.2
Day High/Day Low	9.4 / 9.2	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	13.6 / 6.9	P / Diluted EPS Before XO	
Volume (MM)	5.42	Beta	0.82
Avg. Vol - 3 mo (MM)	14.67		

Financial Information (Currency: USD, in mm)

Revenue - LTM	14,330.2	Cash & ST Invest.	773
EBIT - LTM	-3,076.0	Total Assets	41,500.9
EBITDA - LTM	-209.1	Total Debt	14,313.6
Net Income - LTM	-3,790.1	Total Liabilities	22,865.4
Total Enterprise Value	24,558	Total Equity	18,635.5
TEV/ Total Revenue	1.7 x	Cash from Operations - LTM	2,223.8
TEV/ EBITDA	--	Cash From Investing - LTM	1,889.9
		Cash from Financing -LTM	-4,373.3

**Company Notes**

2014 A1
 GAAP Net Income Includes: (in millions, pre-tax)
 A loss of \$613.000 from Legal Expense/Restructuring
 A loss of \$3.726.000 from Mortgage Settlement
 A loss of \$210.000 from Tax Provision/ Benefit (after-tax)
 A loss of \$240.000 from CVA/DVA (after-tax)
 A loss of \$2.000 from Discontinued Operations

2014 Q4
 GAAP Net Income Includes: (in millions, pre-tax)
 A loss of \$2,800.000 from Legal Expense
 A loss of \$655.000 from Restructuring
 A gain of \$4.000 from CVA/DVA (after-tax)
 A loss of \$1.000 from Discontinued Operations

2014 Q3
 GAAP Net Income includes, (in millions, pre-tax):
 a loss of \$371.000 from CVA/DVA
 a loss of \$1600.000 from Litigation
 a loss of \$382.000 from Restructuring
 a gain of \$0.08 per share from Credit Valuation Adjustments


2014 Q2
 GAAP Net Income includes, (in millions, after-tax):
 a loss of \$3,726.000 from Mortgage Settlement
 a loss of \$20.000 from CVA/DVA
 a loss of \$22.000 from Discontinued Operations

Key Board Members

Name	Title	Organization
W Don Cornwell	Co-Founder Board Member Trustee	Granite Broadcasting Corp Viatrix Inc Edna Mcconnell Clark Foundatio
James Marshall Kilts "Jim"	Founding Partner Founding Partner/Co-Founder Chairman Chairman Board Member Chairman Trustee Board Member	Centerview Partners Centerview Capital Holdings LI Advantage Solutions Inc/Texas Advantage Solutions Inc Viatrix Inc Simply Good Foods Co/The University Of Chicago Cato Inst
Elisha W Finney	Board Member Board Member Board Member Board Member Board Member	Viatrix Inc Mettler-Toledo Intl Inc Nanostring Technologies Inc Icu Medical Inc
Frank A D'Amelio	Senior Advisor Board Member Board Member Board Member Board Member Board Member	Deloitte Llp Viatrix Inc Hewlett Packard Enterprise Co Zoetis Inc Humana Inc Independent College Fund Of Ma
Harry A Korman "Hal"	Board Member	Viatrix Inc
Joellen Lyons Dillon	Board Member	Viatrix Inc
Melina E Higgins	Chairman Chairman Chair Chairman	Antares Capital Corp Antares Capital Lp Viatrix Inc Genworth Financial Inc
Mark W Parrish	Senior Advisor President/Ceo	Frazier Management Llc Intl Federation Of Pharmacutca


Ticker: VTRS US EQUITY		Viatriis Inc										
Period Type		Annuals		Sector: Salud			Industry: Productos farmacéuticos			Sub-Industry: Productos farmacéuticos		
Annals												
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY	
Key Financials												
	Actuals							LTM	Estimates			
For the Fiscal Period Ending	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/03/2025	31/03/2025	31/12/2025	31/12/2026	31/12/2027	
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Rivian Automotive, Inc. es una empresa de tecnología automotriz. Diseña y fabrica furgonetas, camiones y vehículos de servicios públicos, además de ofrecer su												
Total Revenue	11,433.9	11,500.5	11,946.0	17,886.3	16,262.7	15,426.9	14,739.3	3,254.3	14,739.3	3,455.5	3,455.5	
Growth Over Prior Year	(4.0%)	0.6%	3.9%	49.7%	(9.1%)	(5.1%)	(4.5%)	(6.7%)	(9.0%)	(9.0%)	(9.0%)	
Gross Profit	4,001.6	3,897.6	3,796.7	5,575.5	6,497.0	6,438.6	5,623.6	5,280.8	--	--	--	
Margin %	35.0%	33.9%	31.8%	31.2%	40.0%	41.7%	38.2%	162.3%	--	--	--	
EBITDA	3,015.5	2,822.4	2,086.0	4,570.1	4,733.4	3,594.3	2,993.1	(209.1)	1,061.5	1,061.5	1,061.5	
Margin %	26.4%	24.5%	17.5%	25.6%	29.1%	23.3%	20.3%	(6.4%)	7.2%	30.7%	30.7%	
EBIT	905.6	715.5	(210.8)	(34.0)	1,614.9	766.2	10.1	(3,076.0)	916.5	916.5	916.5	
Margin %	7.9%	6.2%	(1.8%)	(0.2%)	9.9%	5.0%	0.1%	(94.5%)	6.2%	26.5%	26.5%	
Earnings from Cont. Ops.	352.5	16.8	(669.9)	(1,269.1)	2,078.6	54.7	(634.2)	(3,790.1)	--	--	--	
Margin %	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	0.4%	(4.3%)	(116.5%)	--	--	--	
Net Income	352.5	16.8	(669.9)	(1,269.1)	2,078.6	54.7	(634.2)	(3,790.1)	436.5	436.5	436.5	
Margin %	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	0.4%	(4.3%)	(116.5%)	3.0%	12.6%	12.6%	
Diluted EPS Excl. Extra Items	0.7	0.0	(1.1)	(1.1)	1.7	0.1	(0.5)	(3.2)	0.5	0.5	0.5	
Growth Over Prior Year	(47.7%)	(95.6%)	--	5.4%	--	(97.1%)	--	5,183.3%	(20.6%)	(20.6%)	(20.6%)	

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	9.28
Shares Out.	1,173.68
Market Capitalization (USD)	10,885.90
- Cash & Short Term Investments	794.00
+ Total Debt	14,466.30
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	24,558.20
Book Value of Common Equity	15,650.40
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	14,466.30
= Total Capital	30,116.70



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual	LTM	Estimates		
	31/03/2025	31/03/2025	31/03/2025	31/03/2025	31/03/2025
TEV/Total Revenue	1.9x	1.7x	7.0x	7.0x	7.0x
TEV/EBITDA	9.5x	--	--	--	--
TEV/EBIT	1447.3x	--	6.6x	6.6x	6.6x
P/Diluted EPS Before Extra	--	--	--	--	--
P/BV	0.8x	0.7x	--	--	--
Price/Tang BV	--	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	9.8x	4.1x	4.1x	4.1x
TEV / EBITDA	0.0x	0.0x	0.0x	0.0x
Price / CF	5.0x	0.0x	0.0x	0.0x
Price / Book	0.7x	0.0x	0.0x	0.0x
Dividend Yield	5.2x	5.2x	5.2x	5.2x



Ticker:	VTRS US EQUITY	VTRS US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatriis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90	17,813.60	16,218.10	15,388.40	14,692.80
Other Revenue	73.10	66.70	109.80	147.70	165.20	130.20	126.10	72.70	44.60	38.50	46.50
Total Revenue	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Cost Of Goods Sold	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30	12,310.80	9,765.70	8,988.30	9,115.70
Gross Profit	3,528.00	4,216.10	4,697.00	4,783.10	4,001.60	3,897.60	3,796.70	5,575.50	6,497.00	6,438.60	5,623.60
Selling General & Admin Exp.	1,593.60	2,083.30	3,171.00	2,562.70	2,391.50	2,542.20	3,452.40	4,858.40	4,183.50	4,761.70	4,804.80
R & D Exp.	581.80	671.90	826.80	783.30	704.50	639.90	555.10	751.10	662.20	805.20	808.70
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	36.40	105.50	-	-
Operating Expense, Total	2,175.40	2,755.20	3,997.80	3,346.00	3,096.00	3,182.10	4,007.50	5,609.50	4,882.10	5,672.40	5,613.50
Operating Income	1,352.60	1,460.90	699.20	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90	766.20	10.10
Interest Expense	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40	573.10	550.00
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Net Interest Exp.	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40	573.10	550.00
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	44.90	206.10	122.70	(0.50)	64.90	43.80	12.60	(5.80)	(1,790.70)	(9.80)	83.30
EBT Excl. Unusual Items	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)	2,813.20	202.90	(623.20)
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)	2,813.20	202.90	(623.20)
Income Tax Expense	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)	604.70	734.60	148.20	11.00
Earnings from Cont. Ops.	933.10	847.70	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60	54.70	(634.20)
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	3.70	0.10	-	-	-	-	-	-	-	-	-
Net Income	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60	54.70	(634.20)
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60	54.70	(634.20)
Abnormal Gains (Losses)	413.00	744.70	1,609.50	629.60	742.90	820.00	1,618.60	1,992.30	(568.10)	1,456.90	1,771.80
Tax Effect on Abnormal Items	(190.84)	(170.02)	(458.13)	(114.69)	(185.76)	57.21	(89.95)	742.12	377.07	(133.17)	(209.48)
NI to Common Excl. Extra Items	1,151.56	1,422.28	1,631.37	1,210.91	909.64	894.01	858.75	1,465.32	1,887.57	1,378.43	928.12
Per Share Items											
Basic EPS	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Basic EPS Excl. Extra Items	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Weighted Avg. Basic Shares Out.	373.70	472.20	513.00	534.50	514.50	515.70	601.20	1,208.80	1,212.10	1,200.30	1,193.30
Diluted EPS	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Diluted EPS Excl. Extra Items	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71	0.05	(0.53)
Weighted Avg. Diluted Shares Out.	398.00	497.40	520.50	536.70	516.50	516.50	601.20	1,208.80	1,217.40	1,206.90	1,193.30
Normalized Basic EPS	3.56	4.30	4.89	4.56	4.58	4.42	3.95	3.70	1.71	2.93	2.68
Normalized Diluted EPS	2.90	2.86	3.13	2.26	1.76	1.73	1.43	1.21	1.55	1.15	0.78
Dividends per Share	-	-	-	-	-	-	-	-	27.99	1,053.28	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	-
Supplemental Items											
EBITA	1,746.40	2,306.90	1,962.80	2,955.30	2,736.00	2,566.30	1,796.30	4,060.60	4,383.90	3,232.20	2,636.10
EBIT	1,352.60	1,460.90	699.20	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90	766.20	10.10
As Reported Total Revenue*	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Effective Tax Rate %	4.25	7.40	-	22.92	-	89.12	-	-	26.11	73.04	-
Normalized Net Income	1,151.56	1,422.28	1,631.37	1,210.91	909.64	894.01	858.75	1,465.32	1,887.57	1,378.43	928.12
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40	180.70	146.10
Stock-Based Comp., Total	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40	180.70	146.10

Ticker:	VTRS US EQUITY
Period Type	Annuals ▾

VTRS US EQUITY	Ascend ▾
Consolidated	Yes ▾

Currency	Reporting	Change	USD
Accounting	Mixed ▾		

Viatriis Inc

	Sector: Salud			Industry: Productos farmacéuticos			Sub-Industry: Productos farmacéuticos				
Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40	701.20	1,259.90	991.90	734.80
Short Term Investments	-	-	83.70	76.70	25.00	26.80	39.10	38.20	35.30	37.00	38.00
Total Cash & ST Investments	225.50	1,236.00	1,082.50	368.80	413.10	502.40	883.50	739.40	1,295.20	1,028.90	772.80
Accounts & Notes Receivable	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80	2,823.80	2,675.30
Total Receivables	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80	2,823.80	2,675.30
Inventories	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90	3,977.70	3,519.50	3,469.70	3,854.10
Prepaid Exp.	2,295.80	596.60	766.40	766.10	518.40	552.00	1,707.40	1,957.60	1,811.20	2,028.10	1,710.50
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	-	-	211.80	362.60	439.50	391.90	913.40	453.80	765.70	3,625.60	508.00
Total Current Assets	6,441.20	6,472.70	7,522.50	7,213.30	6,367.70	6,757.30	12,867.50	10,902.90	10,635.40	12,976.10	9,520.70
Net Property, Plant & Equipment	1,785.70	1,983.90	2,322.20	2,339.10	2,170.20	2,404.20	3,783.50	3,479.40	3,283.80	3,005.20	2,919.20
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	397.40	457.60	633.20	496.80	572.20	703.10	2,147.90	1,332.70	925.90	692.90	753.00
Other Long-Term Assets	7,196.20	13,353.50	24,248.30	25,757.10	23,624.80	21,390.90	42,754.10	39,127.80	35,177.10	31,011.30	28,308.00
Total Assets	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80	50,022.20	47,685.50	41,500.90
LIABILITIES											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	2,803.60	1,078.30	336.40	1,855.40	701.70	1,584.80	3,502.30	3,457.20	1,339.70	2,026.40	95.40
Accounts Payable	905.60	1,109.60	1,348.10	1,452.50	1,617.00	1,528.10	1,904.20	1,657.40	1,766.60	1,938.20	1,853.70
Curr. Income Taxes Payable	160.70	92.40	97.70	121.90	121.50	213.00	288.60	236.90	279.60	226.80	192.70
Other Current Liabilities	1,434.10	1,841.90	3,258.50	2,964.50	2,147.60	2,243.20	4,867.80	4,532.90	3,360.30	3,586.00	3,637.60
Total Current Liabilities	5,304.00	4,122.20	5,040.70	6,385.30	4,587.80	5,569.10	10,562.90	9,884.40	6,746.20	7,777.40	5,779.40
Long-Term Debt	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,390.00	22,658.70	19,918.00	18,196.60	16,353.50	14,218.20
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,412.60	5,377.30	4,547.70	4,007.10	3,087.20	2,867.80
Total Liabilities	12,544.50	12,501.90	23,608.60	22,498.70	20,567.80	19,371.70	38,598.90	34,350.10	28,949.90	27,218.10	22,865.40
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	20.10	1.40	1.40	-	-	-	-	-	-	-	-
Additional Paid In Capital	4,486.10	7,134.10	8,505.30	8,592.00	8,597.40	8,649.60	18,450.90	18,548.20	18,657.90	18,826.90	18,933.90
Retained Earnings	3,614.50	4,462.10	4,942.10	5,644.50	6,010.70	6,031.10	5,361.20	3,688.80	5,175.60	4,639.70	3,418.80
Treasury Stock	(3,857.70)	(67.50)	(67.50)	(567.70)	(999.70)	(999.70)	-	-	-	(251.80)	(504.30)
Comprehensive Inc. and Other	(987.00)	(1,764.30)	(2,263.70)	(361.20)	(1,441.30)	(1,797.20)	(858.00)	(1,744.30)	(2,761.20)	(2,747.40)	(3,212.90)
Total Common Equity	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70	21,072.30	20,467.40	18,635.50
Total Equity	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70	21,072.30	20,467.40	18,635.50
Total Liabilities And Equity	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80	50,022.20	47,685.50	41,500.90
Supplemental Items											
Total Shares Out. on Filing Date	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79	1,200.75	1,193.65
Total Shares Out. on Balance Sheet Date	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79	1,200.75	1,193.65
Book Value/Share	8.68	19.90	20.77	25.39	23.59	23.02	19.02	16.94	17.36	17.05	15.61
Tangible Book Value	(3,140.50)	(2,837.60)	(12,563.50)	(12,143.90)	(11,245.30)	(9,356.70)	(19,076.10)	(17,755.20)	(11,960.60)	(8,580.80)	(7,568.70)
Tangible Book Value/Share	(8.37)	(5.78)	(23.47)	(23.17)	(21.80)	(18.13)	(15.81)	(14.68)	(9.85)	(7.15)	(6.34)
Total Debt	6,650.00	7,373.90	15,539.30	14,720.70	13,862.90	12,974.80	26,161.00	23,375.20	19,536.30	18,379.90	14,313.60
Net Debt	6,424.50	6,137.90	14,456.80	14,351.90	13,449.80	12,472.40	25,277.50	22,635.80	18,241.10	17,351.00	13,540.80
Total Minority Interest	20.10	1.40	1.40	-	-	-	-	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	549.50	592.40	783.40	895.50	955.70	886.80	958.40	922.40	571.50	731.70	1,345.90
Work in Progress Inventory	298.40	387.00	436.00	384.70	369.90	417.20	1,438.10	993.30	755.40	602.10	527.30
Finished Goods Inventory	803.50	971.60	1,237.00	1,262.50	1,254.60	1,366.90	3,075.40	2,062.00	2,192.60	2,135.90	1,980.90
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	25.70	33.60	59.00	75.30	98.20	72.80	159.90	154.50	114.70	118.80	107.60
Full Time Employees	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00	37,000.00	37,000.00	38,000.00	32,000.00

Viartis Inc
Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Cash Flow											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Net Income	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60	54.70	(634.20)
Depreciation & Amort., Total	566.60	1,032.10	1,523.00	1,805.80	2,109.90	2,019.30	2,216.10	4,506.50	3,027.60	2,740.50	2,893.20
Other Non-Cash Adj	(180.70)	415.80	330.10	(174.90)	(109.60)	338.90	427.90	917.80	(1,849.30)	401.50	211.90
Changes in Non-Cash Capital	(300.50)	(287.00)	(285.90)	(262.10)	(11.10)	(571.30)	(742.30)	(1,138.30)	(304.30)	(296.70)	(168.00)
Cash from Ops.	1,014.80	2,008.50	2,047.20	2,064.80	2,341.70	1,803.70	1,231.80	3,016.90	2,952.60	2,900.00	2,302.90
Capital Expenditure	(325.30)	(362.90)	(390.40)	(275.90)	(252.10)	(213.20)	(243.00)	(457.20)	(406.00)	(377.00)	(326.00)
Sale of Property, Plant, and Equipment	-	-	-	-	-	-	2.10	18.30	13.80	14.00	2.70
Cash Acquisitions	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Investment	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	415.80	277.00	-	-	-
Invest. in Marketable & Equity Secur.	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	(475.00)	(1,206.80)	(7,287.40)	(700.50)	(958.30)	(312.20)	(476.00)	44.10	1,912.70	(501.50)	2,124.00
Cash from Investing	(800.30)	(1,569.70)	(7,677.80)	(976.40)	(1,210.40)	(525.40)	(301.10)	(117.80)	1,520.50	(864.50)	1,800.70
Net Short Term Debt Issued/Repaid	(107.80)	(329.20)	40.80	(2.90)	(44.40)	(1.80)	1,099.60	392.10	(1,493.20)	0.30	-
Long-Term Debt Issued	2,235.00	5,510.00	11,752.20	876.10	2,577.90	7.40	983.30	1,710.10	1,875.60	0.30	-
Long-Term Debt Repaid	(2,295.80)	(4,484.10)	(6,296.30)	(2,232.70)	(3,165.20)	(1,108.50)	(2,484.20)	(4,201.30)	(3,662.50)	(1,250.20)	(3,713.70)
Total Debt Issued/Repaid	(168.60)	696.70	5,496.70	(1,359.50)	(631.70)	(1,102.90)	(401.30)	(2,099.10)	(3,280.10)	(1,249.60)	(3,713.70)
Pref. Dividends Paid	-	-	-	-	-	-	-	(399.00)	(581.60)	(575.60)	(574.80)
Total Dividends Paid	-	-	-	-	-	-	-	(399.00)	(581.60)	(575.60)	(574.80)
Increase in Capital Stocks	53.80	97.70	13.80	17.80	17.80	8.10	0.60	-	3.30	3.10	2.50
Decrease in Capital Stocks	-	(67.50)	-	(500.20)	(432.00)	-	-	-	-	(250.00)	(250.00)
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	(165.50)	(155.20)	(175.50)	(23.60)	(66.00)	(81.70)	(171.20)	(544.80)	(58.40)	(232.30)	174.90
Cash from Financing	(280.30)	571.70	5,335.00	(1,865.50)	(1,111.90)	(1,176.50)	(571.90)	(3,042.90)	(3,916.80)	(2,304.40)	(4,361.10)
Net Change in Cash	(65.80)	1,010.50	(295.60)	(777.10)	19.40	101.80	358.80	(143.80)	556.30	(268.90)	(257.50)
Supplemental Items											
Cash Interest Paid	273.80	254.70	357.20	474.00	460.80	470.60	555.40	684.80	642.50	611.60	561.10
Cash Taxes Paid	210.50	302.90	285.60	285.70	228.60	278.60	324.40	641.70	735.20	570.90	514.00
Free Cash Flow	689.50	1,645.60	1,656.80	1,788.90	2,089.60	1,590.50	988.80	2,559.70	2,546.60	2,523.00	1,976.90
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Ticker: VTRS US EQUITY

Period Type: Annuals

Sort: Ascend

Consolidated: Yes

Accounting: Mixed

Viatris Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples												
		31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
TEV / LTM Total Revenue	Close	3.6x	3.5x	3.1x	3.1x	2.4x	2.0x	4.0x	2.2x	2.0x	2.0x	1.9x
	Average	3.8x	4.4x	3.0x	3.1x	2.9x	2.2x	2.0x	3.6x	2.0x	1.9x	2.0x
	High	4.3x	5.7x	3.5x	3.5x	3.4x	2.6x	4.0x	4.0x	2.3x	2.0x	2.2x
	Low	3.5x	3.3x	2.6x	2.7x	2.3x	1.9x	1.7x	2.2x	1.8x	1.8x	1.9x
TEV / LTM EBITDA	Close	14.4x	13.1x	15.7x	11.3x	9.1x	8.1x	23.0x	8.5x	6.7x	8.4x	9.5x
	Average	16.0x	17.6x	11.4x	15.6x	10.5x	8.3x	8.1x	20.5x	7.9x	6.4x	8.7x
	High	18.0x	22.8x	15.7x	17.4x	12.3x	9.9x	23.0x	22.9x	9.0x	8.4x	9.5x
	Low	14.4x	13.1x	9.8x	11.4x	8.6x	7.3x	6.8x	8.5x	6.7x	6.1x	8.2x
TEV / LTM EBIT	Close	20.4x	22.4x	49.9x	25.4x	30.5x	31.5x	--	--	19.6x	39.2x	1447.3x
	Average	23.3x	25.0x	19.6x	49.5x	23.7x	27.6x	31.2x	--	19.6x	18.8x	46.0x
	High	26.2x	32.3x	49.9x	55.4x	30.5x	33.1x	47.6x	--	19.6x	39.2x	1447.3x
	Low	20.4x	19.0x	16.7x	25.8x	19.4x	24.4x	26.6x	--	19.6x	17.7x	37.8x
Price / LTM EPS	Close	19.5x	18.9x	12.2x	18.7x	15.6x	11.6x	13.1x	11.2x	7.2x	9.4x	16.0x
	Average	23.2x	20.0x	15.2x	12.1x	16.8x	12.7x	9.8x	10.2x	9.1x	6.5x	10.2x
	High	27.3x	26.2x	18.9x	18.7x	21.1x	18.3x	13.2x	13.0x	12.7x	9.4x	16.0x
	Low	19.5x	13.5x	12.0x	9.5x	11.6x	9.6x	7.7x	8.5x	7.0x	5.6x	8.8x
Price / Book Value	Close	6.5x	2.7x	1.8x	1.7x	1.2x	0.9x	1.0x	0.8x	0.6x	0.6x	0.8x
	Average	6.3x	6.7x	2.2x	1.8x	1.5x	0.9x	0.7x	0.8x	0.7x	0.6x	0.7x
	High	7.4x	8.8x	2.7x	2.2x	1.9x	1.4x	1.0x	1.0x	0.9x	0.7x	0.8x
	Low	5.3x	2.7x	1.7x	1.4x	1.0x	0.7x	0.6x	0.6x	0.5x	0.5x	0.6x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	--	--	--
	Average	--	--	--	--	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	--	--	--	--	--
	Low	--	--	--	--	--	--	--	--	--	--	--
Price / Cash Flow	Close	20.8x	12.7x	9.6x	11.0x	6.0x	5.7x	9.1x	5.4x	4.6x	4.5x	6.5x
	Average	17.3x	21.3x	10.2x	9.4x	9.8x	4.9x	4.8x	7.1x	4.4x	4.2x	4.9x
	High	20.8x	28.0x	12.7x	11.3x	12.3x	7.1x	9.1x	9.0x	6.2x	5.0x	6.5x
	Low	14.6x	12.7x	8.0x	7.4x	6.0x	3.7x	3.8x	5.4x	3.4x	3.6x	4.2x
TEV / LTM FCF	Close	30.6x	15.5x	11.8x	12.6x	6.7x	6.5x	11.4x	6.4x	5.3x	5.2x	7.5x
	Average	24.8x	31.3x	12.5x	11.7x	11.3x	5.5x	5.5x	8.8x	5.2x	4.8x	5.6x
	High	30.6x	41.2x	15.5x	14.0x	14.2x	7.9x	11.4x	11.3x	7.3x	5.8x	7.5x
	Low	21.0x	15.5x	9.8x	9.2x	6.7x	4.1x	4.3x	6.4x	4.0x	4.2x	4.8x
Dividend Yield	Close	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	4.3	4.4	3.9
	Average	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	4.8	4.1
	High	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	4.3	5.5	4.8
	Low	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	3.9	3.5

Ticker: VTRS US EQUITY		VTRS US EQUITY Ascend ▾			
Period Type: Quarters ▾		Consolidated	Yes ▾	Accounting	Mixed ▾

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10Q	-9Q	-8Q	-7Q	-6Q	-5Q	-4Q	-3Q	-2Q	-1Q	0Q
For the Fiscal Period Ending											
	30/09/2022	31/12/2022	31/03/2023	30/06/2023	30/09/2023	31/12/2023	31/03/2024	30/06/2024	30/09/2024	31/12/2024	31/03/2025
Profitability											
Return on Assets	1.5%	4.0%	3.7%	3.7%	3.8%	0.1%	-0.1%	-1.4%	-1.9%	-1.4%	-8.8%
Return on Capital	2.9%	6.0%	5.7%	5.7%	5.7%	0.5%	-1.1%	-0.5%	-1.1%	-0.6%	-9.9%
Return on Equity	4.0%	10.0%	9.2%	9.1%	9.1%	0.3%	-0.3%	-3.2%	-4.3%	-3.2%	-21.3%
Margin Analysis											
Gross Margin	42.9%	32.9%	41.4%	41.1%	42.9%	41.6%	41.1%	38.1%	38.9%	34.4%	35.7%
SG&A Margin	21.7%	23.7%	22.2%	23.0%	22.3%	24.4%	23.5%	23.7%	22.9%	25.1%	23.9%
EBITDA Margin	27.8%	28.5%	27.4%	28.4%	25.8%	22.7%	21.3%	18.1%	18.8%	18.7%	-1.5%
EBIT Margin	10.4%	9.9%	8.3%	7.2%	5.0%	3.7%	-0.3%	-1.8%	0.1%	-21.5%	-
Earnings from Cont. Ops Margin	13.7%	-5.2%	10.7%	9.4%	11.5%	-11.8%	5.6%	-6.3%	6.0%	-5.1%	-88.6%
Net Income Margin	8.7%	26.1%	6.0%	6.7%	8.4%	-20.0%	3.1%	-8.6%	2.5%	-14.6%	-93.5%
Normalized Net Income Margin	13.9%	13.0%	9.2%	9.3%	14.4%	6.9%	6.2%	8.6%	16.2%	1.6%	4.5%
Free Cash Flow Margin	18.8%	-0.3%	24.8%	11.4%	18.7%	10.8%	15.4%	8.4%	20.0%	9.7%	15.1%
Asset Turnover											
Total Asset Turnover	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x
Fixed Asset Turnover	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x
Accounts Receivable Turnover	6.5x	6.6x	6.8x	6.8x	6.5x	5.1x	5.1x	5.5x	6.7x	6.4x	5.5x
Inventory Turnover	7.7x	7.6x	7.6x	7.7x	7.6x	7.6x	7.6x	7.6x	7.5x	7.5x	7.5x
Short Term Liquidity											
Current Ratio	1.6x	1.6x	1.6x	1.5x	1.6x	1.7x	1.7x	1.5x	1.6x	1.6x	1.7x
Quick Ratio	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x
Cash from Ops. To Fin. Liab.	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x	0.1x
Acc. Cash Sales/Chg.	77.8x	76.0x	76.0x	77.1x	77.1x	77.1x	77.1x	76.0x	76.0x	76.0x	76.0x
Acc. Cash Investments/Chg.	136.7x	140.1x	147.8x	140.4x	137.7x	141.9x	137.9x	134.7x	137.0x	147.0x	158.7x
Acc. Cash Dividends/Chg.	108.4x	107.1x	107.1x	107.1x	107.1x	107.1x	107.1x	107.1x	107.1x	107.1x	107.1x
Acc. Cash Conversion Cycle	151.0x	151.7x	151.7x	148.1x	148.7x	148.7x	148.8x	146.8x	155.7x	147.3x	146.7x
Long Term Solvency											
Total Debt/Equity	100.4%	82.7%	81.0%	80.0%	88.9%	88.8%	81.0%	88.0%	81.0%	76.8%	82.4%
Total Debt/Total	51.4%	47.0%	47.0%	47.0%	47.7%	47.7%	47.7%	47.7%	47.7%	47.4%	48.0%
1/Total/Equity	68.6%	86.4%	87.9%	83.0%	89.6%	89.6%	81.1%	76.5%	73.7%	76.9%	81.7%
1/Total/Total	47.9%	44.8%	45.0%	45.0%	47.1%	47.1%	40.5%	40.5%	41.7%	41.7%	42.9%
Total Liabilities/Total Assets	47.7%	44.8%	45.1%	45.8%	47.7%	48.8%	41.3%	38.0%	38.0%	41.7%	44.5%
EBIT / Interest Exp.	3.66x	-1.57x	2.77x	3.57x	3.19x	-1.73x	1.47x	1.65x	1.55x	-1.50x	-34.45x
EBITDA / Interest Exp.	8.77x	4.54x	7.69x	7.79x	7.69x	6.47x	6.75x	6.77x	6.77x	6.77x	6.77x
EBITDA / APPE / Interest Exp.	7.54x	3.50x	7.56x	6.88x	7.57x	0.17x	6.11x	5.34x	5.62x	3.54x	-19.57x
Total Debt/EBITDA	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x	4.44x
Net Debt/EBITDA	4.71x	3.05x	4.77x	4.87x	4.54x	4.95x	5.76x	5.58x	5.58x	4.66x	—
Adjusted Y. Growth	1.3x	1.1x	1.1x	1.1x	1.0x	1.0x	1.0x	1.1x	1.1x	1.0x	0.9x
Growth Over Nine Year											
Total Revenue	(110.1%)	(110.7%)	(111.0%)	(110.6%)	(110.7%)	(111.0%)	(111.8%)	(111.3%)	(111.4%)	(110.4%)	(111.7%)
Gross Profit	11.1%	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)	(11.76%)
EBITDA	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)	(8.86%)
EBIT	14.1%	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)	(14.1%)
EBT	64.8%	158.4%	(64.8%)	(17.7%)	(18.4%)	175.8%	(64.8%)	(145.0%)	(145.0%)	(64.8%)	(151.1%)
Earnings from Cont. Ops	13.7%	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)
Net Income	13.7%	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)	(13.7%)
Normalized Net Income	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Adjusted EPS before Taxes	11.5%	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)	(11.5%)
Accounts Receivable	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)
Inventory	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)
Net PP&E	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)
Total Assets	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)
Tangible Book Value	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)
Common Equity	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)
Cash from Ops.	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Capital Expenditures	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)
Unlevered Free Cash Flow	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Unlevered Free Cash Flow	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Dividend per Share	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
F&B Over Three Years											
Total Revenue	17.1%	1.4%	(8.3%)	(7.5%)	(12.8%)	(16.0%)	(6.5%)	(4.2%)	(4.1%)	(4.0%)	(6.7%)
Gross Profit	34.1%	3.4%	7.0%	7.0%	7.0%	(7.0%)	7.0%	7.0%	7.0%	7.0%	(7.0%)
EBITDA	36.8%	308.7%	7.1%	(18.8%)	(8.3%)	(16.8%)	(7.1%)	(18.4%)	(15.3%)	(18.8%)	—
EBIT	27.8%	54.8%	—	—	—	—	—	—	—	—	—
EBT	36.8%	(37.7%)	—	—	—	—	—	—	—	—	—
Earnings from Cont. Ops	36.8%	—	—	—	17.4%	147.0%	(46.3%)	—	(17.4%)	(5.0%)	—
Net Income	36.8%	—	—	—	17.4%	147.0%	(46.3%)	—	(17.4%)	(5.0%)	—
Normalized Net Income	36.8%	—	—	—	17.4%	147.0%	(46.3%)	—	(17.4%)	(5.0%)	—
Adjusted EPS before Taxes	36.8%	—	—	—	17.4%	147.0%	(46.3%)	—	(17.4%)	(5.0%)	—
Accounts Receivable	4.0%	(8.7%)	(11.0%)	(10.6%)	(10.8%)	(11.9%)	(11.4%)	(8.7%)	9.5%	(8.7%)	(7.7%)
Inventory	5.0%	(10.6%)	(11.3%)	(9.0%)	(15.3%)	(16.0%)	5.1%	4.5%	9.5%	4.0%	5.7%
Net PP&E	36.8%	36.8%	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)
Total Assets	36.8%	36.8%	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(36.8%)	(11.0%)
Tangible Book Value	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)	(17.7%)
Common Equity	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)	(16.7%)
Cash from Ops.	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Capital Expenditures	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)	(11.7%)
Unlevered Free Cash Flow	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Unlevered Free Cash Flow	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Dividend per Share	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
F&B Over Five Years											
Total Revenue	17.1%	1.4%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%
Gross Profit	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%	17.1%
EBITDA	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%
EBIT	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%	27.8%
Earnings from Cont. Ops	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%
Net Income	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%
Normalized Net Income	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%	36.8%
Adjusted EPS before Taxes	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Accounts Receivable	4.0%	7.1%	7.1%	8.0%	4.0%	7.7%	(10.1%)	(10.1%)	(11.0%)	(8.4%)	(10.8%)
Inventory	5.0%	6.0%	6.0%	6.0%	6.0%	7.7%	(10.1%)	(10.1%)	(11.0%)	(8.4%)	(10.8%)
Net PP&E	16.9%	17.0%	17.0%	17.0%	17.0%	11.0%	(7.8%)	(6.1%)	(5.4%)	(4.0%)	(5.7%)
Total Assets	15.4%	17.0%	17.8%	17.9%	16.0%	(8.7%)	(7.1%)	(7.1%)	(7.1%)	(7.1%)	(15.4%)
Tangible Book Value	(11.7%)	(11.8%)	(11.8%)	(11.8%)	(11.7%)	(12.3%)	(7.7%)	(7.7%)	(7.7%)	(7.7%)	(11.7%)
Common Equity	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%	19.4%
Cash from Ops.	21.7%	(40.0%)	49.4%	10.7%	16.7%	15.7%	(10.7%)	(10.7%)	(10.7%)	(10.7%)	(10.7%)
Capital Expenditures	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%
Unlevered Free Cash Flow	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%
Unlevered Free Cash Flow	11.7%	(16.7%)	46.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%	16.7%
Dividend per Share	—	—	—	—	—	—	—	—	—	—	—
F&B Over Ten Years											
Total Revenue	6.4%	9.7%	6.8%	6.0%	6.0%	8.7%	9.0%	5.9%	4.8%	7.9%	6.4%
Gross Profit	8.7%	8.7%	10.8%	10.7%	11.1%	11.1%	11.1%	11.1%	11.1%	11.1%	11.1%
EBITDA</											

Bloomberg

Company In Depth Fundamentals - Capital Structure Summary

Ticker:	VTRS US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Quarters	Consolidated	Yes	Accounting	Mixed		

Viatriis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

y	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
WACC					
For the Fiscal Period Ending	31/03/2024	30/06/2024	30/09/2024	31/12/2024	31/03/2025
	%	%	%	%	%
Equity					
Cost of Equity	9.2%	9.8%	9.0%	8.8%	8.1%
Weight of Equity	43.8%	42.2%	46.4%	50.9%	41.7%
+ Debt					
Cost of Debt	2.5%	6.6%	5.6%	6.7%	6.4%
Weight of Debt	56.2%	57.8%	53.6%	49.1%	58.3%
+ Preferred Equity					
Cost of Pref Equity					
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	5.4%	7.9%	7.2%	7.8%	7.1%

Capital Structure											
For the Fiscal Period Ending		31/03/2024		30/06/2024		30/09/2024		31/12/2024		31/03/2025	
Currency		USD		USD		USD		USD		USD	
		Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total
Net Market Cap		1,989.9	6.1%	2,455.8	8.2%	1,530.9	5.1%	95.4	0.3%	111.7	0.5%
LT Borrowings		16,228.7	50.0%	14,923.1	49.6%	14,491.5	48.5%	14,218.2	48.7%	14,354.6	57.9%
Pref Equity		0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital		32,432.1	100.0%	30,063.4	100.0%	29,879.9	100.0%	29,174.5	100.0%	24,794.8	100.0%

Debt Summary Data											
For the Fiscal Period Ending		31/03/2024		30/06/2024		30/09/2024		31/12/2024		31/03/2025	
Currency		USD		USD		USD		USD		USD	
	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	
Total Commercial Paper	0.0	0.0%	1,650.0	9.5%	0.0	0.0%	1,650.0	11.5%	1,650.0	11.4%	
Total Revolving Credit	4,000.0	22.0%	4,000.0	23.0%	3,500.0	21.8%	3,500.0	24.5%	3,500.0	24.2%	
Total Capital Leases	-	-	-	-	-	-	0.0%	0.0%	-	-	
General/Other Borrowings	-	-	67.5%	12,522.4	78.2%	64.0%	64.0%	9,316.3	64.4%		
Total Principal Due	18,218.6	100.0%	17,378.9	100.0%	16,022.4	100.0%	14,313.6	100.0%	14,466.3	100.0%	
Total Debt Outstanding	18,218.6		17,378.9		16,022.4		14,313.6		14,466.3		

Additional Totals										
Total Cash & ST Investments	1,053.3	5.8%	955.5	5.5%	1,918.4	12.0%	772.8	5.4%	794.0	5.5%
Net Debt	17,165.3	94.2%	16,423.4	94.5%	14,104.0	88.0%	13,540.8	94.6%	13,672.3	94.5%
Total Short-Term Borrowings	1,989.9	10.9%	2,455.8	14.1%	1,530.9	9.6%	95.4	0.7%	111.7	0.8%
Curr. Port. of LT Debt/Cap. Leases	1,989.9	10.9%	2,455.8	14.1%	1,530.9	9.6%	95.4	0.7%	111.7	0.8%
Lone-Term Debt (incl. Cap. Leases)	16,228.7	89.1%	14,923.1	85.9%	14,491.5	90.4%	14,218.2	99.3%	14,354.6	99.2%
Total Secured Debt	--	--	--	--	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--	--	--	--	--

Credit Ratios					
Net Debt/EBITDA	5.2x	5.9x	5.6x	4.7x	--
Total Debt/EBITDA	5.6x	6.3x	6.3x	4.9x	--
Operating Income/Total Debt	0.0x	0.0x	0.0x	0.0x	-0.2x
LTM FCF/Total Debt	0.1x	0.1x	0.1x	0.1x	0.1x
LTM FCF/Total Debt	0.1x	0.1x	0.1x	0.2x	0.2x
FRIT/Interest Expense	1.5x	-1.6x	1.6x	-1.5x	-25.0x
FRIT/Total Interest Expense	1.5x	-1.6x	1.6x	-1.5x	-25.0x
Degree of Financial Leverage	3.1x	--	2.8x	--	--
EBITDA/CAPEX/Interest Expense	6.1x	3.3x	5.6x	3.5x	-19.6x
EBITDA/Total Interest Expense	6.5x	3.7x	6.2x	4.7x	-19.2x

Debt Schedule										
Debt Schedule in Yr 1	1,888.0	5.3%	1,071.0	3.2%	1,114.0	3.6%	0.0	0.0%	0.0	0.0%
Debt Schedule in Yr 2	1,289.0	3.6%	1,286.0	3.8%	325.0	1.0%	1,929.0	7.0%	1,942.0	14.1%
Debt Schedule in Yr 3	2,514.0	7.1%	2,499.0	7.4%	1,953.0	6.3%	1,630.0	5.9%	1,669.0	12.2%
Debt Schedule in Yr 4	1,667.0	4.7%	1,661.0	4.9%	1,666.0	5.5%	1,527.0	5.5%	1,561.0	11.4%
Debt Schedule in Yr 5	1,559.0	4.4%	1,553.0	4.6%	1,585.0	5.1%	0.0	0.0%	0.0	0.0%
Debt Schedule - Years 2 - 3	3,803.0	10.7%	3,765.0	11.2%	2,278.0	7.3%	3,559.0	12.9%	3,611.0	26.3%
Debt Schedule - Years 4 - 5	3,226.0	9.2%	3,214.0	9.5%	3,281.0	10.6%	1,527.0	5.5%	1,561.0	11.4%
Debt Schedule - Years 2 - 5	7,029.0	19.8%	6,999.0	20.8%	5,559.0	17.9%	5,086.0	18.4%	5,172.0	37.7%
Debt Schedule Beyond Yr 5	8,549.0	24.1%	8,539.0	25.3%	8,592.0	27.7%	8,494.0	30.7%	8,552.0	62.3%
Debt Schedule - Total Debt	35,436.6	100.0%	33,700.3	100.0%	31,015.1	100.0%	27,627.2	100.0%	13,732.5	100.0%

Capital Lease Schedule	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
------------------------	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

Duration/Lease (Rental Expense) Schedule									
Rental Expense - Year 1	--	--	--	--	--	78.2	26.3%	--	--
Rental Expense - Year 2	--	--	--	--	--	71.1	23.9%	--	--
Rental Expense - Year 3	--	--	--	--	--	46.4	15.6%	--	--
Rental Expense - Year 4	--	--	--	--	--	25.6	8.6%	--	--
Rental Expense - Year 5	--	--	--	--	--	16.8	5.6%	--	--
Rental Expense - Years 2 - 3	--	--	--	--	--	117.5	39.5%	--	--
Rental Expense - Years 4 - 5	--	--	--	--	--	42.4	14.2%	--	--
Rental Expense - Years 2 - 5	--	--	--	--	--	159.9	53.7%	--	--
Rental Expense Beyond Year 5	--	--	--	--	--	59.5	20.0%	--	--
Total Sublease Income	--	--	--	--	--				
Future Min Oper Lease Obligations	--	--	--	--	--	297.6	100.0%		

Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2-3	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 4-5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	--	--	--	--
Total Contractual Obligations	--	--	--	--	--	--	--	--	--	--

Purchase Obligations	--	--	--	--	--	--	--	--	--	--
----------------------	----	----	----	----	----	----	----	----	----	----

Interest Rate Data					
W/Ave. Interest Rate - Lone-term Debt	--	--	--	--	--

Ticker:VTRS US EQUITY

VTRS US EQUITYAscend

CurrencyReportingChangeUSD

Period TypeAnnuals

ConsolidatedYes

AccountingMixed

Viatisr Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE											
Revenue by Product							31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Revenue	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Brands	6,510.40	9,429.30	10,967.10	11,760.00	-	5,362.10	5,289.50	10,841.30	9,889.60	9,800.50	9,200.30
Generics	51.10	-	109.80	147.70	-	4,796.90	5,234.90	5,630.20	5,015.10	5,587.90	5,492.50
Other Sources	-	-	-	-	-	1,211.30	1,295.50	1,342.10	1,313.40	38.50	46.50
#N/A Field Not Applicable	-	-	-	-	-	130.20	126.10	72.70	44.60	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
Revenue by Geography											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Revenue	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70	15,426.90	14,739.30
Developed Markets	4,548.40	5,100.40	5,629.50	5,876.20	3,865.20	8,240.00	8,510.90	10,428.70	9,768.90	9,251.90	8,929.40
Emerging Markets	1,621.30	4,848.90	5,385.60	4,969.60	1,164.80	3,965.90	3,746.10	3,144.70	2,615.60	2,551.60	2,250.70
-	1,476.80	3,413.80	4,507.40	4,683.70	1,092.70	1,723.20	1,853.80	2,212.80	2,201.20	2,160.40	2,166.50
-	73.10	2,205.60	2,953.80	3,958.30	-	1,192.50	1,195.30	2,027.40	1,632.40	1,424.50	1,346.20
-	-	2,056.60	2,383.80	2,832.10	-	385.70	476.00	72.70	44.60	38.50	46.50
-	-	1,033.40	985.80	1,082.60	-	130.20	126.10	-	-	-	-
-	-	66.70	109.80	147.70	-	-	-	-	-	-	-
-	-	66.50	88.30	117.50	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker:	VTRS US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annually	Consolidated	Yes	Accounting	Mixed		

Viatis Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	5.00	11.90	17.40	20.10	19.20	20.70	23.50	38.60	32.60	26.60	28.40
Interest Cost	2.60	4.00	8.20	13.60	13.00	13.60	13.50	31.60	36.80	63.60	59.70
Expected Return on Plan Assets	(1.70)	(6.40)	(10.90)	(14.30)	(14.40)	(12.10)	(19.90)	(66.10)	(64.60)	(62.60)	(67.10)
Pension Expense (Income)	7.00	11.80	13.40	18.20	17.90	22.00	18.60	(10.20)	7.80	7.60	11.00
Other Postretirement Cost											
Service Cost	0.50	0.60	0.60	0.70	0.60	0.60	1.20	3.40	3.40	2.10	1.50
Interest Cost	1.00	1.10	1.30	1.60	1.50	1.50	1.40	2.60	3.70	6.90	5.30
Expected Return on Plan Assets	-	-	-	-	-	-	-	-	-	-	-
Other Postretirement Benefits Expense (I	-	-	2.20	-	2.30	5.50	2.90	6.20	2.90	6.90	1.00
Pension Funded Status											
Fair Value of Plan Assets	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10	1,109.40	1,100.50
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	28.90	26.40	58.20	97.00	25.60	41.70	40.40
Benefits Paid	--	--	--	--	(24.90)	(23.90)	(24.60)	(52.80)	(54.10)	(74.00)	(83.30)
Projected Benefit Obligation	--	234.40	632.90	665.20	635.40	674.70	2,145.80	1,946.60	1,379.00	1,443.60	1,366.30
Over(Under) Funded Pension	--	(72.40)	(341.20)	(369.10)	(351.90)	(359.00)	(791.20)	(580.20)	(311.90)	(334.20)	(265.80)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	69.11	46.09	44.51	44.62	46.79	63.13	70.19	77.38	76.85	80.55
Other Postretirement Funded Status											
Fair Value of Plan Assets	--	-	-	-	-	-	-	-	-	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	2.50	9.40	1.70	18.30	10.20	11.10	12.60
Benefits Paid	(1.60)	(2.00)	(2.20)	(2.70)	(2.70)	(2.50)	(1.60)	(20.70)	(14.70)	(15.20)	(14.40)
Projected Benefit Obligation	--	--	--	--	34.00	33.80	188.80	188.40	137.50	112.60	128.20
Over(Under) Funded Post Ret Benefits	--	(26.00)	(38.00)	(35.10)	(34.00)	(33.80)	(188.80)	(188.40)	(137.50)	(112.60)	(128.20)
Other Post-Retirement Funding Ratio	--	--	--	--	-	-	-	-	-	-	-
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	--	--	--	--	4.90	4.30	4.30	5.10	5.00	6.10	6.30
Discount Rate used on Plan Liabilities	--	--	--	--	2.30	1.60	1.90	2.30	4.80	4.50	4.60
Rate of Compensation Increase	--	--	--	--	2.90	2.90	2.90	3.10	3.70	3.70	3.70
Other Postretirement Benefits											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	3.70	4.30	3.30	1.90	2.30	5.00	5.50
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10	1,109.40	1,100.50
Asset Category - Equities %	--	--	--	--	43.92	28.29	45.28	40.33	37.14	38.93	26.40
Asset Category - Debt %	--	--	--	--	43.67	56.98	43.70	45.15	42.46	41.24	58.63
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	1.38	1.24	3.82	4.76	3.29	1.57	0.92
Asset Category - Other %	--	--	--	--	11.04	13.49	7.19	9.76	17.11	18.26	14.06
Expected Pension Payments											
Year 1	--	--	--	--	32.00	33.20	104.50	101.80	93.10	100.60	99.80
Year 2	--	--	--	--	34.20	34.00	102.30	97.10	96.10	99.10	95.70
Year 3	--	--	--	--	35.70	34.70	104.90	103.00	97.90	97.50	102.60
Year 4	--	--	--	--	34.00	35.20	108.60	100.70	98.30	105.20	97.20
Year 5	--	--	--	--	36.40	38.90	106.90	104.30	102.00	100.80	98.00
Beyond Year 5	--	--	--	--	192.10	193.10	526.20	528.50	518.10	521.40	494.30
Expected Postretirement Benefits											
Year 1	--	--	--	--	1.70	2.00	16.40	16.10	15.40	13.80	12.50
Year 2	--	--	--	--	1.70	1.80	16.60	16.50	15.80	13.80	13.10
Year 3	--	--	--	--	2.00	1.90	16.50	16.90	15.80	13.70	13.50
Year 4	--	--	--	--	2.30	1.90	16.60	16.80	15.70	13.10	13.10
Year 5	--	--	--	--	2.20	2.00	16.30	16.60	15.10	12.40	12.60
Beyond Year 5	--	--	--	--	11.60	10.20	71.40	73.00	64.50	50.50	57.10

Ticker:	VTRS US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

[illegible]